CharlesFBarishMDFACP, FACG, AGAF

eConsultant in Gastroenterology for ConferMED; Retired Physician, Researcher, Educator (Wake Gastroenterology, Wake Research Associates, UNC School of Medicine)

Join to view full profile

Dr. Barish is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Barish's full profile

Already have an account?

Office
Retired
Boynton Beach, FL 33473

Summary

Dr. Barish joined Wake Gastroenterology/Wake Internal Medicine Consultants in Raleigh, NC in 1985 and founded Wake Research Associates (currently M3 Wake Research) that same year. He retired from Wake Gastroenterology in 2018 at which time he joined the faculty of the UNC School of Medicine in Chapel Hill as Assistant Professor of Medicine in the Division of Gastroenterology and Hepatology. At UNC, he mentored gastroenterology fellows for a year, until his full retirement in June 2019.

As a practicing gastroenterologist, Dr. Barish treated most GI disorders but had a particular interest in the diagnosis and management of inflammatory bowel disease. He was active in clinical research throughout his career and authored and co-authored numerous articles regarding GI diseases in various medical journals and books. As of March 2024, there have been more than1500 citations of his journal articles which ranks in the top 10% of citations within the Doximity community. Dr. Barish is also listed as a Top Doctor with US News and World Report, Castle Connolly, Becker's GI and Endoscopy, Guide to Americas Top Physicians and American Registry’s Top 5% of “Most Honored Professionals”. He was also one of the first physicians recognized in the Bridges to Excellence IBD Care Recognition Program, sponsored by the American Gastroenterological Association’s Health Care Incentives Improvement Institute.

Since September 2019, Dr. Barish has been doing eConsults in Gastroenterology through ConferMED, a division of the Moses/Weitzman Health System. These are consultations for rural physicians in the United States who have limited access to specialists.

Post by wakeinternalmedicineconsultants.

Wake Internal Medicine Consultants, Inc.

Dr. Barish comments on retiring from practice after 33 years.

Education & Training

Wake Forest University Baptist Medical CenterFellowship, Gastroenterology, 1983 - 1985
Wake Forest University Baptist Medical CenterResidency, Internal Medicine, 1981 - 1983
Wake Forest University Baptist Medical CenterInternship, Internal Medicine, 1980 - 1981
University of Florida College of MedicineClass of 1980
University of FloridaBS, Chemistry, 1976
University of FloridaB.S., Chemistry, With High Honors, 1976

Certifications & Licensure

ME State Medical License 2022 - 2027
NC State Medical License 1981 - 2024
FL State Medical License 1984 - 1985
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Gastroenterology

Awards, Honors, & Recognition

American Registry, Top Doctors Castle Connolly, 2012-2019
America’s Most Honored Professionals – Top 5% American Registry with Various Organizations that assemble peer review ratings and patient reviews, 2017-2018
US News and World Report's "Top Doctors" 2012-2018
Guide to America's Top Physicians Consumers’ Research Council of America, 2007-2018
Biographical record in Marquis: "Who's Who in America" 1998-2018
Biographical record in Marquis: “Who’s Who in Medicine and Healthcare” Marquis, 1997-2018
Top MD Consumers Checkbook, 2013
Fellow (FACP) American College of Physicians, 1992
Bridges to Excellence Inflammatory Bowel Disease Care Recognition Program American Gastroenterological Association’s Health Care Incentives Improvement Institute, 2013
Fellow (AGAF) American Gastroenterological Association, 2006
Fellow (FACG) American College of Gastroenterology, 1992
Premier Physician Award for Promotion of Research and Compassionate Healthcare, Carolinas Chapter CCFA 1997
Alpha Omega Alpha Honor Medical Society 1980
B. S. Degree with High Honors 1976
Phi Kappa Phi Honor Society 1974
Alpha Epsilon Delta Premedical Honor Society 1974
Join now to see all

Clinical Trials

YM443 in Subjects With Functional Dyspepsia Start of enrollment: 2004 Mar 10
Completed
Phase 2
A Study of the Safety and Effectiveness of DDP733 in Treating IBS With Constipation in Females Start of enrollment: 2007 Oct 01
Unknown status
Phase 2, Phase 3
Evaluation of Clinical Equivalence Between Two Lubiprostone Products Start of enrollment: 2011 May 01
Completed
Phase 3
The Plecanatide Chronic Idiopathic Constipation (CIC) Study Start of enrollment: 2011 Oct 01
Completed
Phase 2, Phase 3
Efficacy and Safety Study With Diltiazem Hydrochloride Cream to Treat Anal Fissures Start of enrollment: 2012 Oct 01
Completed
Phase 3
The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C) Start of enrollment: 2012 Nov 01
Completed
Phase 2
Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC) Start of enrollment: 2013 Aug 01
Completed
Phase 3
ERADICATE Hp - Treating Helicobacter Pylori With RHB-105 Start of enrollment: 2013 Nov 01
Completed
Phase 3
12-Week Study of Plecanatide for CIC (The CIC3 Study) Start of enrollment: 2013 Nov 01
Completed
Phase 3
Pharmacodynamic, Pharmacokinetic, and Tolerability Study of a Liquid Form of Lubiprostone in Adult Subjects With Chronic Idiopathic Constipation Start of enrollment: 2013 Oct 01
Completed
Phase 3
Multicenter Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray in Women With Diabetic Gastroparesis Start of enrollment: 2014 Mar 27
Completed
Phase 3
Multicenter Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray in Men With Diabetic Gastroparesis Start of enrollment: 2014 Apr 01
Completed
Phase 3
Evaluation of the Efficacy and Safety of Lubiprostone in Adults With Mixed or Unsubtyped Irritable Bowel Syndrome Start of enrollment: 2015 Feb 01
Terminated
Phase 2
Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment Start of enrollment: 2015 Sep 22
Terminated
Phase 3
A Study to Evaluate the Safety, Tolerability and Microbiome Dynamics of SER-287 in Subjects With Mild-to-Moderate Ulcerative Colitis Start of enrollment: 2016 Jan 13
Completed
Phase 1
Efficacy, Safety, and Pharmacokinetics of APT-1011 in Subjects With Eosinophilic Esophagitis (EoE) Start of enrollment: 2017 Jun 22
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

Correction to: Capsule and Sprinkle Formulations of Lubiprostone Are Not Biologically Similar in Patients with Functional Constipation.
Atoya Adams, Charles F. Barish, Angel Chen, Patrick Dennis, Richard Krause
Advances in Therapy. 2021-05-24
1 citations
Capsule and Sprinkle Formulations of Lubiprostone Are Not Biologically Similar in Patients with Functional Constipation
Atoya Adams, Charles F. Barish, Angel Chen, Patrick Dennis, Richard Krause
Advances in Therapy. 2021-04-08
5 citations
Plecanatide Is Effective and Safe in the Treatment for Chronic Idiopathic Constipation: Results of a Phase II Trial
Charles F. Barish, Spencer D. Dorn, Ronald Fogel, Reema Patel, Jonathan Rosenberg
Digestive Diseases and Sciences. 2021-02-01

Journal Articles

Long-term Treatment with Plecanatide was Safe and Tolerable in Patients with Irritable Bowel Syndrome with Constipation
Barish, C.F., Crozier R., Griffin P, Curr Med Res Opin, 10/2018
Economic and Medical Resource Use (MRU) Burden of Iron Deficiency Anemia (IDA) in a Bariatric Surgery Population in the United States
• Knight T., D'Sylva L., Barish C. F, . Gastroenterology, 1/1/2014
Economic and Medical Resource Use (MRU) Burden of Iron Deficiency Anemia (IDA) in an Inflammatory Bowel Disease (IBD) Population in the United States
Knight T., D'Sylva L., Barish C. F., Gastroenterology, 1/1/2014
Economic and Medical Resource Use (MRU) Burden of Iron Deficiency Anemia (IDA) in a Bariatric Surgery Population in the United States
Knight T., D'Sylva L., Barish C. F., Gastroenterology, 1/1/2014
Nitroglycerin 04% Ointment vs Placebo in the Treatment of Pain Resulting From Chronic Anal Fissure: a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study
Berry S. M., Barish C. F., Bhandari R., Clark G., Collins G., Howell J., Pappas J. E., Riff D., Safdi M., Yellowlees A., BMC Gastroenterology, 1/1/2013
A Multi-center, Randomized, Active-Controlled Study to Investigate the Efficacy and Safety of Intravenous Ferric Carboxymaltose in Patients with Iron Deficiency Anemia
Onken J., Bregman D., Harrington R., Morris D., Acs, P, Akright B., Barish C., Transfusion, 1/1/2013
Comparative Review of the Safety and Efficacy of Ferric Carboxymaltose Versus Standard Medical Care for the Treatment of Iron Deficiency Anemia in Bariatric and Gastri...
Malone M., Barish C., He A., Bregman D., Obesity Surgery, 1/1/2013
Safety and Efficacy of Intravenous Ferric Carboxymaltose (750 mg) in the Treatment of Iron Deficiency Anemia: Two Randomized, Controlled Trials
Barish C. F., Koch T., Butcher A., Morris D., Bregman D., Anemia, 1/1/2012
Efficacy and Safety of Lubiprostone in Patients with Chronic Constipation
Barish C.F., Drossman D., Johanson J. F., Ueno R., Digestive Diseases and Sciences, 1/1/2010
Use of Adalimumab in Crohn's Related Cavitary and Granulomatous Lung Disease
Barish C., American J Gastroenterology, 1/1/2009
Safety and Tolerability of Concurrent Natalizumab Treatment for Patients with Crohn's Disease Not in Remission While Receiving Infliximab
Sands B.E., Kozarek R., Spainhour J., Barish C.F., Becker S., Goldberg L, Katz S., Goldblum R., Harrigan R., Hilton D., Hanauer S.B., Inflammatory Bowel Diseases, 1/1/2007
A Phase 1/2A Trial of STA-5326, an Oral IL-12/23 Inhibitor, in Patients with Active Moderate to Severe Crohn's Disease
Burakoff R., Barish C., Riff D., Pruitt R., Chey W., Farraye F., Shafran I., Katz S., Krone C., Stevens C., Sherman M., Jacobson E., Bleday R., Inflammatory Bowel Diseases, 1/1/2006
Alicaforsen Therapy in Inflammatory Bowel Disease
Barish C., Expert Opinion on Biologic Therapy, 1/1/2005
An Open-Label, Dose-Ranging Study of Sta-5326, An Oral Interleukin-12 Inhibitor, for the Treatment of Patients With Moderate To Severe Crohn's Disease
Burakoff R., Barish C., Farraye F., Pruitt R., Shafran Il, Dahl T., Hsia A., Sherman M., Bleday R., Gastroenterology, 1/1/2005
Two Phase 3 Studies of Alicaforsen (ISIS-2302), An Antisense Oligonucleotide To Human ICAM-1, in the Treatment of Moderate To Severe Crohn's Disease
Chey W., Volfova M., Konecny M., Rdyzewska G., Fogel R., Pare P., Barish C, et al, Gastroenterology, 1/1/2005
Safety and Tolerability of Natalizumab in Patients Concurrently Receiving Infliximab in a Phase 2 Study of Active Crohn's Disease
Sands B., Kozarek R., Spainhour J., Barish C., Becker S., Goldberg L., Katz S., Hanauer S., et. al., American J Gastroenterology, 1/1/2004
Semapimod Treatment of Crohn's Disease
Buchman A., Katz S., Barish C., Elkin R., Korzenik J., Plasse T., Gastroenterology, 1/1/2004
Dose Ranging Pharmacokinetic Trial of High Dose Alicaforsen (Intercellular Adhesion molecule-1 Antisense Oligodeoxynucleotide) (ISIS 2302) in Active Crohn's Disease
Yacyshyn B., Barish, C., Goff, J., Dalke, D., et.al., Alimentary Pharmacol and Therapeutics, 1/1/2002
Randomized, Controlled Trial of Recombinant Human Interleukin-11 In Patients with Active Crohn's Disease
Sands B, Winston B., Salzberg B., Barish C., et. al., Alimentary Pharma and Therapeutics, 1/1/2002
High Dose Safety and Pharmacokinetic Study of ISIS 2302 in Crohn's Disease
Barish C., Goff J., Dalke D., Gaspari M., et.al., American J Gastroenterology, 1/1/2002
Suggested Therapeutic Benefit of (rhIL-11) in Patients with Crohn's Disease
Sands B., Winston B., Salzberg B., Barish C, Gastroenterology, 1/1/1999
A Randomized, Double-Masked, Placebo-Controlled Study of Recombinant Human Interleuken Eleven (RHIL-11) in Crohn's Disease Subjects Not Receiving Prednisone
Sands B., Winston B., Salzberg B., Barish C., et. al., Gastroenterology, 1/1/1999
The ChemTrak Hp Chek Fingerstick Whole Blood Serology Test for the Detection of Helicobacter Pylori Infection
Chey W., Murthy U. K., Unscheer W., Barish C., et. al., American J Gastroenterology, 1/1/1998
Ranitidine for Erosive Esophagitis: A Double Blind, Placebo-controlled Study
Roufail W., Belsito A., Robinson M., Barish C., Rubin, A., Alimentary Pharmacol and Therapeutics, 1/1/1992
Graded Esophageal Balloon Distention: A New Provocative Test for Noncardiac Chest Pain
Barish, C. F., Castell, D. O., Richter, J. E., Digestive Diseases and Sciences, 1/1/1986
Join now to see all

Books/Book Chapters

Gastroesophageal Reflux Disease-Pathogenesis, Diagnosis, Therapy
Chapter: Complications of Gastroesophageal Reflux.
Page 281 - 300Barish, C. F., Wu, W.C.Editors: Castell, D.O., Wu, W. C., Ott, D. J..Futura Publishing Company, New York1985
Complications of Gastroesophageal Reflux.
Chapter: Gastroesophageal Reflux Disease – Pathogenesis, Diagnosis,
Page 281 - 300Barish, C. F., Wu, W.CEditors: Castell, D.O., Wu, W. C., Ott, D. J.New York: Futura Publishing Company

Abstracts/Posters

Efficacy and Safety of Intravenous Ferumoxytol for the Treatment of Iron Deficiency Anemia in Patients with IBD
David Hetzel D., Barish C.F., Dahl N., Bernard K., Lau G., Advances in Inflammatory Bowel Diseases 2013 Annual Meeting, Hollywood, FL, 12/14/2013
Do CRNAs need on site MD anesthesia supervision for safe propofol sedation in an ambulatory endoscopy? A comparison of 2 sedation models: CRNA alone and CRNA with MD a...
Parekh M, Anderson E, Miller S.P., Barish C.F., Patel R.S., ACG 2013 annual meeting, San Diego, CA, 10/12/2013
Phase III, Randomized, Placebo-Controlled Evaluation of Ferumoxytol Treatment for Iron Deficiency Anemia in Patients who have a History of Unsatisfactory Oral Iron The...
Barish C.F., DeBusk K., Strauss W., Lau G., Bernard K., Dahl N.V., ACG 2013 annual meeting, San Diego, CA, 10/12/2013
Do CRNAs need on site MD anesthesia supervision for safe propofol sedation in an ambulatory endoscopy center (AEC)? A comparison of 2 sedation models: CRNA alone and C...
Parekh M, Anderson E, Miller S.P., Barish C.F., Patel R.S., ACG 2013 Annual Meeting, 1/1/2013
Phase III, Randomized, Placebo-Controlled Evaluation of Ferumoxytol Treatment for Iron Deficiency Anemia in Patients who have a History of Unsatisfactory Oral Iron The...
Barish C.F., DeBusk K., Strauss W., Lau G., Bernard K., Dahl N.V., ACG 2013 Annual Meeting, 1/1/2013
Phase III, Randomized, Placebo-Controlled Evaluation of Ferumoxytol Treatment for Iron Deficiency Anemia in Patients who have a History of Unsatisfactory Oral Iron The...
Barish C.F., DeBusk K., Strauss W., Lau G., Bernard K., Dahl N.V., Obesity Society 2013 Annual Meeting, 1/1/2013
Efficacy and Safety of Intravenous Ferumoxytol for the Treatment of Iron Deficiency Anemia in Patients with IBD.
David Hetzel D., Barish C.F., Dahl N., Bernard K., Lau G., Strauss W., Advances in Inflammatory Bowel Diseases 2013 Annual Meeting, 1/1/2013
A Randomized, Double-Blind, Placebo-Controlled Pilot Phase 2 Study of CCX282-B in Patients with Moderate to Severe Crohn's Disease.
Hanauaer S., Wolf D., Katz S., Pruitt R., Souder R., Barish C., Eyring E., Goff J., Hansen R., Hommes D., Keshav S., et. al., Gastroenterology, 1/1/2006
CCX282-B, An Orally Active Inhibitor of Chemokine Receptor CCR9, In A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study in Moderate to Severe Crohn's Disease.
Keshav S., Wolf D., Katz S., Pruitt R., Souder R., Barish C., Eyring W., Goff J., Hansen R., Hommes D., Sanders M., Ungashe S., Zheng W., Bekker P., Schall T., United European Gastroenterology, 1/1/2006
A Randomized , Double-Blind, Placebo-Controlled Pilot Phase 2 Study of CCX282-B in Patients with Moderate to Severe Crohn’s Disease.
Hanauaer S., Wolf D., Katz S., Pruitt R., Souder R., Barish C., Eyring E., Goff J., Hansen R., Hommes D., Keshav S., et. al, Gastroenterology
Delay in Return to Baseline Weight After Colonoscopy Preparation May Be a Risk for Dehydration.
Barish C. F, Gastroenterology
CCX282-B, An Orally Active Inhibitor of Chemokine Receptor CCR9, In A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study in Moderate to Severe Crohn’s Disease.
Keshav S., Wolf D., Katz S., Pruitt R., Souder R., Barish C., Eyring W., Goff J., Hansen R., Hommes D., Sanders M., Ungashe S., Zheng W., Bekker P., Schall T, United European Gastroenterology
Dehydration With Bowel Purgatives: A Risk for Polyethylene Glycol (PEG) and Sodium Phosphate (NaP) Formulations.
Barish C. F. , Walker K, American J Gastroenterology
Clinical Laboratory Evaluation of a New Sodium Phosphate (NaP) Tablet Bowel Purgative Vs a 2L Polyethylene Glycol Electrolyte Lavage Solution (PEG) Plus Bisacodyl.
Rubin D., Barish C., Lottes S., Forbes B, American J Gastroenterology
Join now to see all

Lectures

Burden of Iron Deficiency Anemia in a Bariatric Surgery Population in the United States.
New Orleans, LA - 1/1/2013
Safety and Efficacy of High Dose Intravenous Ferric Carboxymaltose vs. Standard Medical Care in the Treatment of Iron Deficiency Anemia.
Washington, DC - 1/1/2011
Use of Adalimumab in Crohn's-Related Cavitary and Granulomatous Lung Disease.
San Diego, CA - 1/1/2009
Dehydration With Bowel Purgatives: A Risk for Polyethylene Glycol (PEG) and Sodium Phosphate (NaP) Formulations.
Las Vegas, NV - 1/1/2006
High Dose Safety and Pharmacokinetic Study of ISIS 2302 in Crohn's Disease.
Raleigh, NC - 1/1/2002
The Immune System in Inflammatory Bowel Disease.
Raleigh, NC - 1/1/1995
Progressive Esophageal Balloon Distention in Evaluation of Noncardiac Chest Pain.
New York City, NY - 1/1/1986
On the Mechanism of Esophageal Chest Pain: Evidence for Abnormal Sensory Perception.
Washington, DC - 1/1/1985
Esophageal Balloon Distention as a Provocative Test for Noncardiac Chest Pain.
New Orleans, LA - 1/1/1985
Esophageal Function in Health and Disease.
Society for Gastrointestinal Endoscopy Assistants of North Carolina
Safety and Efficacy of High Dose Intravenous Ferric Carboxymaltose vs. Standard Medical Care in the Treatment of Iron Deficiency Anemia .
American College of Gastroenterology
Progressive Esophageal Balloon Distention in Evaluation of Noncardiac Chest Pain
American Gastroenterological Association, (May 1985), (May 1986), (April 1985), (January 1985)
Update on Pathophysiology and Treatment of Inflammatory Bowel Disease.
Crohn’s and Colitis Foundation of America, (March 1995), (November 2001)
High Dose Safety and Pharmacokinetic Study of ISIS 2302 in Crohn’s Disease .
American College of Gastroenterology
Clinical Laboratory Evaluation of 48 g Oral INKP-102 Compared to 60 g Visicol as a Bowel Purgative Prior to Colonoscopy.
American College of Gastroenterology
A Risk for Polyethylene Glycol (PEG) and Sodium Phosphate (NaP) Formulations .
American College of Gastroenterology
Clinical Laboratory Evaluation of a New Sodium Phosphate (NaP) Tablet Bowel Purgative Vs a 2 L Polyethylene Glycol Electrolyte Lavage Solution (PEG) Plus Bisacodyl.
American College of Gastroenterology
Use of Adalimumab in Crohn’s-Related Cavitary and Granulomatous Lung Disease .
American College of Gastroenterology
An Open-Label, Multi-Center, Randomized, 7-Day Crossover Study Comparing the Preference and Safety of Powder and Liquid Lactulose in Adult Patients with Chronic Consti...
American Gastroenterological Association
Join now to see all

Other

Dysphagia and Weight Loss, a Particular Concern for the Elderly.
Barish, C.F., Castell, D.O., Medical Times
1/1/1985